Holen Sie sich die Stockscreener-App
45.43
0.68%
-0.3557
Schlusskurs vom Vortag:
$45.79
Offen:
$45.78
24-Stunden-Volumen:
524.47K
Relative Volume:
0.15
Marktkapitalisierung:
$19.44B
Einnahmen:
$2.38B
Nettoeinkommen (Verlust:
$1.32B
KGV:
25.52
EPS:
1.7806
Netto-Cashflow:
$897.24M
1W Leistung:
-0.85%
1M Leistung:
+0.82%
6M Leistung:
+25.49%
1J Leistung:
+36.12%
1-Tages-Spanne:
$45.35
$45.97
1-Wochen-Bereich:
$45.31
$46.44
52-Wochen-Spanne:
$29.66
$47.86
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
45.38 | 19.62B | 2.38B | 1.32B | 897.24M | 1.7806 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.54 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.00 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
680.44 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.02 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
281.47 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | UBS | Neutral → Buy |
| 2025-09-30 | Eingeleitet | Goldman | Buy |
| 2025-05-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
Royalty Pharma plc (RPRX) earns $51 target as 2026 growth outlook exceeds expectations - MSN
[144] Royalty Pharma plc SEC Filing - Stock Titan
UBS and Citi are bullish on Royalty Pharma plc (RPRX) – here’s why - MSN
54,266 Shares in Royalty Pharma PLC $RPRX Acquired by WBI Investments LLC - MarketBeat
ROYALTY PHARMA PLC-CL A (NASDAQ:RPRX) Shows High Technical and Setup Ratings Ahead of Potential Breakout - ChartMill
Royalty Pharma names Greg Butz as EVP of partnering, investments By Investing.com - Investing.com South Africa
Royalty Pharma Announces Expansion of Leadership Team - The Manila Times
Royalty Pharma hires Bank of America healthcare banking executive - StreetInsider
Royalty Pharma PLC $RPRX Shares Bought by L2 Asset Management LLC - MarketBeat
Royalty Pharma Plc Experiences Valuation Adjustment Amid Strong Market Performance Metrics - Markets Mojo
Dorsey Asset Management LLC Buys Shares of 2,350,449 Royalty Pharma PLC $RPRX - MarketBeat
Clark Capital Management Group Inc. Makes New Investment in Royalty Pharma PLC $RPRX - MarketBeat
182,068 Shares in Royalty Pharma PLC $RPRX Acquired by Braidwell LP - MarketBeat
Swiss National Bank Sells 22,000 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma : TD Cowen Conference Transcript - marketscreener.com
Royalty Pharma Plc Experiences Valuation Adjustment Amidst Competitive Market Dynamics - Markets Mojo
Royalty Pharma PLC $RPRX Shares Bought by Korea Investment CORP - MarketBeat
A Look At Royalty Pharma (RPRX) Valuation After New Asia Expansion Leadership Appointment - Sahm
Magnetar Financial LLC Takes Position in Royalty Pharma PLC $RPRX - MarketBeat
Russell Investments Group Ltd. Grows Position in Royalty Pharma PLC $RPRX - MarketBeat
The Bull Case For Royalty Pharma (RPRX) Could Change Following Asia Leadership Hire To Target Biotech Royalties - simplywall.st
WINTON GROUP Ltd Takes $3.36 Million Position in Royalty Pharma PLC $RPRX - MarketBeat
Capital International Investors Raises Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Purchased by Capital International Sarl - MarketBeat
Price-Driven Insight from (RPRX) for Rule-Based Strategy - Stock Traders Daily
Royalty Pharma PLC $RPRX is Regal Partners Ltd's 10th Largest Position - MarketBeat
Royalty Pharma PLC $RPRX Stock Position Decreased by Rhenman & Partners Asset Management AB - MarketBeat
Neo Ivy Capital Management Buys New Position in Royalty Pharma PLC $RPRX - MarketBeat
Goodman Advisory Group LLC Purchases New Stake in Royalty Pharma PLC $RPRX - MarketBeat
CM Management LLC Takes $1.76 Million Position in Royalty Pharma PLC $RPRX - MarketBeat
Revolution Medicines To Get Up To $2B For Development Of Cancer Drug From Royalty Pharma - MSN
Morgan Stanley Raises Royalty Pharma (RPRX) Price Target, Maintains Overweight Rating - MSN
Royalty Pharma Plc Hits New 52-Week High of USD 47.86 - Markets Mojo
Vera Therapeutics Appoints Christopher Hite to Board of Directors - GlobeNewswire Inc.
Royalty Pharma (NASDAQ:RPRX) Reaches New 12-Month HighStill a Buy? - MarketBeat
Royalty Pharma Plc Hits New 52-Week High of USD 47.66 - Markets Mojo
RPRX SEC FilingsRoyalty Pharma Plc 10-K, 10-Q, 8-K Forms - Stock Titan
Royalty Pharma (NASDAQ:RPRX) CFO Terrance Coyne Sells 34,791 Shares - MarketBeat
Insider sales of common stock — Repare Therapeutics (NASDAQ: RPRX) - Stock Titan
Victory Capital Management Inc. Purchases 165,727 Shares of Royalty Pharma PLC $RPRX - MarketBeat
RPRX Earnings History & Surprises | EPS & Revenue Results | ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) - ChartMill
Royalty Pharma at TD Cowen Conference: Strategic Growth Insights - Investing.com Nigeria
Royalty Pharma plc (RPRX) Earns $51 Target as 2026 Growth Outlook Exceeds Expectations - Yahoo Finance
RPRX Technical Analysis & ETF Price Forecast - Intellectia AI
Royalty Pharma (RPRX) Passes Through 2% Yield Mark - Nasdaq
Royalty Pharma Plc Hits New 52-Week High of USD 46.37 - Markets Mojo
TD Asset Management Inc Acquires 91,136 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Quantbot Technologies LP Makes New $2.82 Million Investment in Royalty Pharma PLC $RPRX - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Buys 44,289 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX) Achieves Record Growth and Hits Investment Targets Ahead of Schedule - Finviz
Royalty Pharma appoints Kenneth Sun to lead Asia expansion By Investing.com - Investing.com Australia
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Royalty Pharma Plc-Aktie (RPRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Coyne Terrance P. | EVP & CFO |
Mar 02 '26 |
Sale |
46.78 |
34,791 |
1,627,534 |
45,761 |
1.42%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):